Treatment costs associated with hospital-based intravenous immunoglobulin therapy compared to home-based subcutaneous immunoglobulin therapy in a cohort of paediatric patients with primary immunodeficiency by Ducruet, Thierry et al.
MEETING ABSTRACT Open Access
Treatment costs associated with hospital-based
intravenous immunoglobulin therapy compared
to home-based subcutaneous immunoglobulin
therapy in a cohort of paediatric patients with
primary immunodeficiency
Thierry Ducruet
1, Marie-Claude Levasseur
2, Anne Des Roches
2, Renée Dicaire
2, Elie Haddad
2*
From Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting 2011
Quebec, Canada. 20-23 October 2011
Objectives
To assess the direct and indirect costs associated with
hospital-based IVIg therapy compared to home-based
SCIg in a cohort of patients with PID from hospital/
government and family perspectives.
Methods
This is a retrospective study on a cohort of patients with
PID. Annual costs associated with IVg therapy were
assessed for each patient for the year prior to commencing
home-based subcutaneous SCIg therapy and the year after
for the costs associated with the SCIg therapy. Demo-
graphic and clinical information were collected from
patient’s chart. Economic data were captured from admin-
istrative databases, patients, families, and healthcare provi-
ders. Paired t-tests and non-parametric Wilcoxon tests
were used to assess the difference in costs.
Results
Twenty-eight children were enrolled in the study. Mean
(SD) age at initial diagnosis was 6.9 (4.2) years. Median
duration since Ig therapy initiation was 24 months. The
study showed a decrease in costs when shifting from IVIg
to SCIg therapy from hospital/government and patients
perspectives. The mean difference in costs between the
two periods was -$ 4,346 (-$ 6,097; -$ 2,597), p<0.001.
The mean difference was statistically significant for both
government and family perspectives: -$ 2,602 (p<0.001)
and -$ 1,744 (p=-0.002), respectively. The absence of dif-
ference in hospital admissions confirms that both strate-
gies are similar in effectiveness and safety.
Conclusions
The home-based subcutaneous therapy is a safe and
cost-effective strategy. Shifting from hospital-based IVIg
therapy to home-based SCIg therapy resulted in decreas-
ing costs from both hospital/government and family
perspectives. Long-term impact on the health system is
substantial.
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